Evidence Table E62. Binge eating disorder drug treatment – part 8

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Arnold, 200266 | Weight (kg) (M,SD)  BMI (M,SD) | Weight, kg, mean (SD):  G1: 110.4 (24.1)  G2: 103.5 (19.0)  (P = NS)  BMI, kg/m², mean(SD):  G1: 39.6 (7.0)  G2: 36.7 (6.8)  (P = NS) | Weight, kg, mean (SE):  G1: 112.5 (25.0)  G2: 110.3 (18.2)  Diff between groups (P = NR)  Diff between groups in change over time (time trend analysis, P = 0.001; endpoint analysis, P < 0.0001), G1 better than G2  BMI, kg/m², mean (SD):  G1: 40.0 (7.2)  G2: 39.5 (6.3)  Diff between groups (P = NR)  Diff between groups in change over time (time trend analysis, P < 0.0001; endpoint analysis, P < 0.0001), G1 better than G2 | NA | NA | NA |

Evidence Table E62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Brownley, 201367 | Weight (kg) | Weight (kg):  Baseline  G1: 99.9 (21.8)  G2: 96.3 (26.8)  G3: 100.0 (16.1)  p = 0.93 | Weight (kg):  Monthly rate of change  G1: 0.19 (0.25)  G2: -0.13 (0.23)  G3: 0.55 (0.25)  p = ns | Fasting gluclose (mg/dL)  Glycated hemoglobin (HbA1c %) | Fasting glucose (mg/dL):  baseline  G1: 90.6 (10.0)  G2: 92.8 (13.8)  G3: 91.4 (8.4)  p = 0.99  HbA1c:  baseline  G1: 5.5 (0.3)  G2: 5.7 (0.5)  G3: 5.5 (0.4)  p = 0.99  Overall: 5.6 (0.4) | Fasting glucose (mg/dL):  Monthly rate of change  G1: -1.08 (0.80)  G2: -0.67 (0.74)  G3: 2.53 (0.80)  G1 v G3  t: -3.19  df: 35  p < 0.01  G2 v G3  t: -2.93  df: 35  p <0.01  HbA1c:  6 months  overall: 5. 6 (0.4) |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Guerdjikova, 200968 | Weight (kg)  Body Mass Index | Weight,kg (M,SD)  G1: 105.93 (19.08)  G2: 120 (25.39)  BMI (M, SD)  G1: 38.72 (5.38)  G2: 41.52 (7.24) | Weight,kg (M,SD)  G1: 104.55 (19.30)  G2: 119.95 (25.86)  Diff between groups (p = 0.166)  Diff between groups in change over time (p =0.207)  Weight loss, kg (M, SD)  G1: 1.17 (2.96)  G2: 0.15 (3.61)  p=NS  BMI (M,SD)  G1: 38.24 (5.70)  G2: 41.50 (7.42)  Diff between groups (p =0.189)  Diff between groups in change over time (p =0.236) | Glucose (mg/dl)  Insulin (mmU/ml)  Total cholestrol (mg/dl)  HDL (mg/dl)  LDL (mg/dl)  Triglycerides (mg/dl)  Leptin (ng/ml)  Ghrelin (ng/dl) | Glucose (mg/dl) (M,SD for this & all variables below)  G1: 97.88 (39.30)  G2: 84.42 (13.58)  Insulin (mmU/ml)  G1: 12.80 (9.08)  G2: 12.38 (5.94)  Total cholestrol (mg/dl)  G1: 200.25 (48.20)  G2: 195.23 (46.85)  HDL (mg/dl)  G1: 58.54 (16.33)  G2: 51.63 (11.42)  LDL (mg/dl)  G1: 155.33 (212.04)  G2: 120.54 (21.58)  Triglycerides (mg/dl)  G1: 144.46 (69.92)  G2: 154.58 (67.44)  Leptin (ng/ml)  G1: 39.49 (21.41)  G2: 42.00 (29.39)  Ghrelin (ng/dl)  G1: 722.61 (187.28)  G2: 704.00 (260.07) | Glucose (mg/dl) (M,SD)  G1: 87.60 (16.61)  G2: 90.29 (8.20)  p=0.027 (endpoint analysis for this variable and all below)  Insulin (mmU/ml) (M,SD)  G1: 11.64 (9.14)  G2: 13.26 (7.26)  p=0.010  Total cholestrol (mg/dl) (M,SD)  G1: 185.07 (38.43)  G2: 200.00 (29.12)  p=0.177  HDL (mg/dl) (M,SD)  G1: 58.54 (16.33)  G2: 51.63 (11.42)  p=0.493  LDL (mg/dl) (M,SD)  G1: 104.87 (33.17)  G2: 117.94 (27.2)  p=0.809  Triglycerides (mg/dl) (M,SD)  G1: 124.73 (67.31)  G2: 161.06 (77.54)  p=0.015  Leptin (ng/l) (M,SD)  G1: 33.09 (23.26)  G2: 38.97 (27.05)  p=0.220  Ghrelin (ng/l) (M,SD)  G1: 753.21 (208.59)  G2: 695.40 (234.25)  p=0.350 |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Guerdjikova, 200869 | Weight (kg)  BMI (kg/m2) | Weight (kg), M(SD)  G1: 113.0 (20.0)  G2: 109.2 (17.2)  p=NS  BMI (kg/m2), M(SD)  G1: 40.1 (6.8)  G2: 40.3 (4.8)  p=NS | Weight (kg), M (SD)  G1: 112.0 (20.0)  G2: 109.8 (17.8)  Time-trend analysis  Estimate between-group difference in 12-week change (95% CI): 2.1 (0.8, -3.4)  chi-square: 8.41  p=0.002  Endpoint analysis  Estimate between-group difference in change from BL to final visit (95% CI): 1.7 (0.1, -3.2)  t=3.14  p=0.037  Completers analysis change in weight from BL to 12wk  G1: -1.1 (2.9) kg  G2: 0.7 (2.5) kg  p=0.037  BMI (kg/m2), M(SD)  G1: 40.4 (7.0)  G2:40.5 (5.0)  Time-trend analysis  Estimate between-group difference in 12-week change (95% CI): 0.7 (0.3, -1.2)  chi-square: 8  p=0.003 | Fasting measures of  -insulin  -glucose  -triglycerides  -LDL cholesterol  -total cholesterol  -leptin  -ghrelin | Insulin , µU/mL, M (SD)  G1: NR  G2: NR  p=NS  Glucose, mg/dL, M (SD)  G1: NR  G2: NR  p=NS  Triglycerides, mg/dL, M (SD)  G1: NR  G2: NR  p=NS  LDL cholesterol, mg/dL, M (SD)  G1: NR  G2: NR  p=NS  Total cholesterol, mg/dL, M (SD)  G1: NR  G2: NR  p=NS  Leptin, ng/mL, M (SD)  G1: 43.1 (SD 16.1)  G2: 42.9 (SD 18.3)  p=NS  Ghrelin, ng/L, M (SD)  G1: 818.6 (SD 369.5)  G2: 821.9 (SD 343.8)  p=NS | Insulin mean change from BL to final visit, µU/mL  G1: -0.2  G2: 2.3  p=NS  Glucose mean change from BL to final visit, mg/dL  G1: -0.3  G2: -2.3  p=NS  Triglycerides mean change from BL to final visit, mg/dL  G1: -6.6  G2: 3.1  p=NS  LDL cholesterol mean change from BL to final visit, mg/dL  G1: 2.8  G2: 7.6  p=NS  Total cholesterol mean change from BL to final visit, mg/dL  G1: 4.8  G2: 10.5  p=NS |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes | |
| Guerdjikova, 200869  (continued) |  |  | Endpoint analysis  Estimate between-group difference in change from BL to final visit (95% CI): 0.6 (0.0, -1.1)  t= 2.03  p=0.048 |  |  | | Leptin mean change from BL to final visit, ng/mL  G1: 0.1  G2: 2.9  p=NS  Ghrelin mean change from BL to final visit, ng/L  G1: -1.6  G2: 71.8  p=NS |
| Guerdjikova, 201270 | Weight (kg)  BMI (kg/m2) | Weight (kg)  G1: 111.1 (24.1)  G2: 118.3 (23.1)  p = NR  BMI (kg/m2)  G1: 38.7 (6.8)  G2: 42.8 (7.6)  p = NR | Weight (kg)  G1: 108.3 (23.8)  G2: 118.0 (23.2)  Longitudinal Analysis  d = 0.66  p = 0.04  Endpoint Analysis  d = 0.59  p = 0.07  BMI (kg/m2)  G1: 37.7 (7.5)  G2: 42.9 (7.3)  Longitudinal Analysis  d = 0.53  p = 0.11  Endpoint Analysis  d = 0.58  p = 0.08 | NA | NA | | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Hudson, 199871 | Body Mass Index (BMI) | BMI, kg/m², M (SD)  G1: 34.2 ( 6.0)  G2: 36.8 (SD 8.2) | BMI, kg/m², M (SD)  Treatment-by-time interaction:  -0.167 (SE 0.083)  p=0.04 | NA | NA | NA |
| Leombruni, 200872 | Weight (kg)  Body Mass Index (BMI) | Weight  G1: 101.9 (12.5)  G2: 99.6 (14.5)  BMI  G1: 40.2 (3.9)  G2: 38.6 (3.8) | Weight  T8  G1: 98.3 (12.6)  G2: 96.1 (16.3)  T12  G1: 97.4 (13.6)  G2: 95.5 (17.5)  T24  G1: 98.6 (14.8)  G2: 94.7 (17.8)  time effect p<0.002  time x group effect p<0.576  BMI  T8  G1: 38.8 (3.9)  G2: 37.2 (3.9)  T12  G1: 38.4 (4.2)  G2: 36.9 (4.1)  T24  G1: 38.5 (5.0)  G2: 36.6 (4.3)  time effect p<0.001  time x group effect p<0.569 | NA | NA | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200773 | Weight, kg  Body Mass Index (BMI) | Weight, mean (SD):  G1: 106.9 (20.2)  G2: 116.6 (30.1)  BMI, mean (SD):  G1: 37.3 (6.7)  G2: 41.4 (8.5) | Weight  Longitudinal Analysis  Estimate (mean change btwn g1 - g2): -3.09  95% CI: -5.46 to -0.72  X^2: 6.61  p: 0.10  Endpoint Analysis  Estimate (mean change btwn g1-g)2: -2.69  95% CI: -4.88 to 0.49  t: 2.48  p: 0.018  BMI  Longitudinal Analysis  Estimate (mean change btwn g1 - g2): -1.03  95% CI: -1.86 to -0.20  X^2: 5.93  p: 0.016  Endpoint Analysis  Estimate (mean change btwn g1-g)2: -0.89  95% CI: -1.66 to 0.12  t: 2.34  p: 0.025 | NR | NR | NR |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200674 | Weight (kg)  Body mass index (BMI) | Weight (kg), mean (SD):  G1: 118.0 (SD 30.7)  G2: 112.8 (SD 24.3)  p=NR, NS  BMI, mean (SD):  G1: 42.7 (SD 9.5)  G2: 40.6 (SD 7.6)  p=NR, NS | Weight (kg)  Longitudinal analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -2.86 (95% CI -4.57 to -1.14)  p<0.001  Endpoint analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): -3.68 (95% CI -5.91 to -1.45)  p=0.002  BMI | Leptin, ng/mL  Ghrelin, ng/L  Glucose, mg/dL  insulin microUnits/mL  triglycerides, mg/dL  LDL cholesterol, mg/dL  total cholesterol, mg/dL | Leptin, ng/mL, mean (SD)  G1: 29.1 (SD 9.7)  G2: 27.1 (SD 7.8)  p=NR, NS  Ghrelin, ng/L, mean (SD):  G1: 995.7 (SD 216.0)  G2: 934.7 (SD 212.0)  p=NR, NS  Glucose, insulin, triglycerides, LDL cholesterol, total cholesterol, all = NR | Ghrelin change from baseline, mean:  G1: 98.6  G2: -156.8  t=4.0, p=0.001  Leptin change from baseline, mean:  G1: -5.1  G2: -1.1  p=NR, NS  Insulin change from baseline, mean:  G1: 15.7  G2: 8.4  p=NR, NS  Glucose change from baseline, mean:  G1: 0.4  G2: -1.1  p=NR, NS  Triglycerides change from baseline, mean:  G1: -4.5  G2: -12.2  p=NR, NS  LDL cholesterol change from baseline, mean:  G1: 7.2  G2: 2.9  p=NR, NS |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes | |
| McElroy, 200674  (continued) |  |  | Longitudinal analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -1.02 (95% CI -1.64 to -0.41)  p=0.001  Endpoint analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): -1.32 (95% CI -2.07 to -0.56)  p<0.001 |  |  | | Total cholesterol change from baseline, mean:  G1: 8.5  G2: -5.4  p=NR, NS |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200375 | Body Mass Index (BMI)  Weight | BMI, kg/m2, mean (SD)  G1: 41.4 (6.9)  G2: 34.2 (7.4)  p = 0.003  Weight, kg, mean (SD)  G1: 116.8 (21.0)  G2: 94.6 (23.2)  p = 0.004 | BMI, kg/m2, mean (SD)  G1: 40.9 (7.0)  G2: 35.7 (7.5)  Time Trend Analysis:  Mean difference between groups in rate of change: -0.525 (SE 0.145)  p < 0.001  Endpoint Analysis:  Mean difference between groups in change from BL to 6wk: -0.818 (SE 0.254)  p = 0 .001  Weight (kg), mean (SD)  G1: 114.1 (22.4)  G2: 99.8 (24.7)  Time Trend Analysis:  Mean difference between groups in rate of change: -1.43 (SE 0.40)  p < 0.001  Endpoint Analysis:  Mean difference between groups in change from BL to 6wk: -2.49 (SE 0.66)  p < 0.001 | NA | NA | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200376 | Body mas index (BMI)  Weight (kg)  Body Fat, % | Weight, mean (SD)  G1: 120.4 (18.3)  G2: 123.4 (24.4)  BMI, mean (SD)  G1: 44.2 (7.1)  G2: 42.0 (6.7) (note, error in manuscript table 1, BMI = 2.0)  Body fat = NR | BMI  G1: NR  G2: NR  Diff between groups, p = NR  Diff between groups in rate of change, p = 0.003  Greater improvements for G1  Weight loss kg, mean  G1: 5.9  G2: 1.2  Diff between groups, p = NR  Diff between groups in rate of change, p = 0.005  Body Fat  Percent, p = 0.005  Total, p = 0.001  Greater improvements for G1 | Diastolic blood pressure  Insulin (mmu/ml)  Glucose (mg/dl)  Cholesterol (mg/dl)  Triglycerides (mg/dl)  Total cholesterol (mg/dl) | NR | Diastolic blood pressure change, mmHg, mean:  G1: -2.71  G2: 0.47  p = 0.04  All other measures, p = NS  Insulin change, microunits/mL), mean:  G1: -5.78  G2: -0.76  Glucose change, mg/dL, mean:  G1: -2.4  G2: 0.82  LDL Cholesterol change, mg/dL, mean:  G1: -8.40  G2: -0.44  Triglyceride change, mg/dL, mean:  G1: -27.2  G2: -8.06  Total cholesterol change, mg/dL, mean:  G1: -17.13  G2: -2.13 |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200077 | Body mass index (BMI), kg/m2 | BMI, mean (SD):  G1: 36.4 (7.4)  G2: 35.8 (7.5) | BMI, mean (SD):  Diff in change between G1 & G2, mean: -0.596  SE: 0.189  p = 0.002  G1 better than G2 | NR | NR | NR |
| McElroy, 201178 | Weight, kg  Body mass index (BMI), kg/m2 | Weight, mean (SD):  G1: 116.5 (27.3)  G2: 107.7 (23.7)  p = 0.28  BMI, mean (SD):  G1: 39.8 (7.5)  G2: 39.2 (8.4)  p = 0.71 | Longitudinal Analysis:  Weight, mean (SD):  G1: 116.3 (27.6)  G2: 108.9 (24.3)  p = 0.44  BMI, mean (SD):  G1: 39.7 (7.4)  G2: 39.7 (8.9)  p = 0.32  Endpoint Analysis:  Weight, mean (SD):  p = 0.40  BMI, mean (SD):  p = 0.35 | NA | NA | Mean change from baseline to final visit  All p = NR, stated NS  Insulin, microInternationalUnits/mL  G1: 3.7  G2: 0  Glucose, mg/dL  G1: 0  G2: 0  Triglycerides, mg/dL  G1: 9.8  G2: 10.4  LDL cholesterol, mg/dL  G1: 0.1  G2: 0.4  Total cholesterol, mg/dL  G1: 1.3  G2:1.0 |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 200779 | Weight, kg  Body mass index (BMI), kg/m2 | Weight, kg, ean (SD)  G1: 106 (18.5)  G2: 107 (18.3)  BMI, mean (SD)  G1: 38 (5.1)  G2: 39 (5.5) | Longitudinal Analysis, rate of change  Weight  G1 better than G2, rate of reduction  p < 0.001  BMI  G1 better than G2, rate of reduction  p < 0.001 | NA | NA | NA |
| McElroy, 201380 | Weight (kg)  Body mass index (BMI), kg/m2  Waist circumference (cm) | Weight (kg), mean (SD)  G1: 106.0 (13.5)  G2: 107.6 (17.7)  p=0.70  BMI, mean (SD)  G1: 38.6 (4.8)  G2: 39.2 (6.4)  p=0.69  Waist circumference (cm), mean (SD)  G1: 114.1 (9.9)  G2: 115.2 (12.1)  p=0.70 | Weight (kg), mean change (SD) from baseline to endpoint  G1: -0.03 (2.02)  G2: -0.23 (3.16)  p=0.76  BMI, mean change (SD) from baseline to endpoint  G1: 0.01 (0.69)  G2: -0.07 (1.27)  p=0.75  Waist circumference (cm), mean change (SD) from baseline to endpoint  G1: -0.95 (4.14)  G2: -0.57 (3.54)  p=0.74 | NA | NA | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| McElroy, 201581 | Weight (kg) | Weight (kg)  G1: 98.5 (SD 18.65)  G2: 100.6 (SD 18.84)  G3: 98.4 (SD 16.70)  G4: 96.8 (SD 17.28) | 11wk Mean change in body weight  G1: -3.1 (SD 3.64)  G2: -4.9 (SD 4.43)  G3: -4.9 (SD 3.93)  G4: -0.1 (SD 3.09)  11wk Mean % reduction in body weight, difference from placebo, LS change, mean (SE)  G1: 3.268% (SE 0.7197%)  G2: 5.179% (SE 0.7214%)  G3: 5.282% (SE 0.7229%)  G4: N/A  11wk Mean change in body weight: Significant difference compared with placebo  G1 p<0.001  G2 p<0.001  G3 p<0.001  G4 N/A | None | None | None |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| Pearlstein, 200382 | Weight (lbs) | Weight, lbs (M, SD)  G1: 243 (85)  G2: 258 (96)  (P = NS) | Weight, lbs (M, SD)  G1: 242 (82)  G2: 262 (99)  Diff between groups (P = NR)  Change over time for both groups: (P = NS)  Diff between groups in change over time (P = NS) | NA | NA | NA |
| Shire, 201483,84 | Body weight | LBS  G1: 208.9  G2: 205.3  KG  G1: 94.8  G2: 93.1 | Change in body weight  G1: -5.57% (0.350)  G2: -0.15% (0.353)  Mean diff: -5.41 (-6.39 to -4.44)  (p < 0.001) | NA | NA | NA |
| Shire, 201484,85 | Body weight | LBS  G1: 208.9  G2: 205.3  KG  G1: 94.8  G2: 93.1 | Change in body weight  G1: -5.57% (0.350)  G2: -0.15% (0.353)  Mean diff: -5.41 (-6.39 to -4.44)  (p < 0.001) | NA | NA | NA |

Evidence Table 62. Binge eating disorder drug treatment – part 8 (continued)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Weight Related Measure(s) | Weight Related Baseline | Weight Related Outcomes | Definition of Biomarker Outcomes Other Than Weight | Biomarker Outcomes Other Than Weight Baseline | Biomarker Outcomes Other Than Weight Outcomes |
| White, 201386 | BMI  Weight | BMI  G1: 36.2 (SD 6.6)  G2: 35.4 (SD 7.1)  Weight  G1: NR  G2: NR | 8wk  G1: 35.7 (SD 6.6)  G2: 35.2 (SD 7.4)  % BMI loss  G1: 1.8 (2.6)  G2: 0.6 (2.1)  Mixed effects model medication effect  Percent BMI loss F=10.57, p=0.00  8wk weight  G1: NR  G2: NR  Mean (SD) weight loss (kg)  G1: 1.68 (2.69)  G2: 0.43 (2.12)  p=NR, stated as significant | NA | NA | NA |